Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

pembrolizumab 130Carboplatin 106Paclitaxel 65Cisplatin 61Gemcitabine 59Pemetrexed 57Bevacizumab 54Docetaxel 49Fluorouracil 43Oxaliplatin 41atezolizumab 37Dexamethasone 36Leucovorin 34Cetuximab 33130-nm albumin-bound paclitaxel 33Nivolumab 30Cyclophosphamide 30Prednisone 29Rituximab 28Capecitabine 28durvalumab 27Fulvestrant 24Lenalidomide 22enzalutamide 21Letrozole 21Irinotecan 21venetoclax 20Doxorubicin 19ribociclib 18pomalidomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × daromun × 30 days × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡